HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An overview on the implementation of HPV vaccination in Europe.

Abstract
The discovery that the Human PapillomaVirus (HPV) is the necessary cause of cervical cancer has led to the development of prophylactic vaccines. Cervical cancer is the second most common cause of death from cancer among young women in Europe: mortality is still high, despite its important reduction due to screening programs for early detection. Besides cervical cancer, HPV is responsible for a significant proportion of other anogenital cancers and an increasing number of oropharyngeal cancers, representing together an at least equal burden compared to cervical cancer. HPV is also responsible for conditions such as condyloma acuminata (genital warts) and recurrent respiratory papillomatosis. Organized vaccination programs against HPV have the potential to prevent about 70% of cervical cancers and the vast majority of the other HPV-related conditions. Recommendations for HPV vaccination of at least one cohort of females have been issued in nearly all western European countries, and national/regional publicly funded vaccination programs have been introduced in most of them. Different approaches have been chosen for the implementation of HPV vaccination, based on the organization of each country's health care system. A brief outline of these programs in Europe is presented. As for all preventive public health interventions, high coverage of the target population with HPV vaccines pre-exposure is essential to achieve maximum reduction of cases: therefore, in order to obtain the maximum and most equitable coverage and future benefit, programs targeting adolescents before exposure to HPV should be preferred and population-based. Catch-up programs should also be implemented wherever possible, in order to deliver more and even earlier benefits, and effective communication strategies need to be adopted.
AuthorsPaolo Bonanni, Miriam Levi, Nina B Latham, Angela Bechini, Emilia Tiscione, Piero Lai, Donatella Panatto, Roberto Gasparini, Sara Boccalini
JournalHuman vaccines (Hum Vaccin) 2011 Jan-Feb Vol. 7 Suppl Pg. 128-35 ISSN: 1554-8619 [Electronic] United States
PMID21245659 (Publication Type: Journal Article, Review)
Chemical References
  • Papillomavirus Vaccines
Topics
  • Europe (epidemiology)
  • Female
  • Humans
  • Immunization Programs
  • Papillomavirus Infections (complications, epidemiology, mortality, prevention & control)
  • Papillomavirus Vaccines (administration & dosage, immunology)
  • Uterine Cervical Neoplasms (epidemiology, immunology, mortality, prevention & control)
  • Vaccination (statistics & numerical data)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: